AbCellera Biologics Inc. (ABCL) Stifel 2026 Healthcare Conference 2026 November 10, 2026 7:00 PM EST
Company Participants
Carl L. Hansen – CEO, President & Chairperson
Conference Call Participants
Stephen Willey – Stifel, Nicolaus & Company, Incorporated, Research Division
Presentation
Stephen Willey
Stifel, Nicolaus & Company, Incorporated, Research Division
All right. Good morning, everyone. I’m Stephen Willey, one of the senior biotech analysts here at Stifel. I’m glad to have with us to kick off day 2, CEO of AbCellera, Carl Hansen. So Carl, thanks for joining us. I’m not sure if there’s any — some opening statements you’d like to make before we jump right into Q&A.
Carl L. Hansen
CEO, President & Chairperson
Thanks for having me, Steve. Yes, maybe, just really quickly, for those that don’t know, AbCellera is a biotech company located in Vancouver. We have, over the years, built a platform for the development of antibody medicines. I believe we have a very significant competitive advantage in solving some difficult problems.
And the mission of the company is to apply that internally and to repeatedly invent, develop and ultimately commercialize breakthrough medicines. So we’ve made a transition recently, and I think we’re going to talk today about ABCL635, which we view as the first evidence of that.
Question-and-Answer Session
Stephen Willey
Stifel, Nicolaus & Company, Incorporated, Research Division
We’re going to spend a lot of time on 635 if that’s okay with you. All right. So you top line the data. This is the Phase II data back in August. I think it took a lot of us by surprise in a very good way. Maybe, you can just kind of walk us through the high points of the data and how those efficacy and safety metrics compare to the standard of care oral small molecules that are on the market?
Credit: Source link
